Illumina Launches Billion Cell Atlas to Accelerate Drug Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: NASDAQ.COM
- Genome Dataset Launch: Illumina's introduction of the Billion Cell Atlas aims to accelerate drug discovery through AI, with plans to create the most comprehensive map of human disease biology over the next three years, significantly enhancing R&D efficiency in the pharmaceutical sector.
- Strategic Partnerships: The initiative is built under an alliance framework with AstraZeneca, Merck, and Eli Lilly, indicating that collaborative efforts within the industry will drive advancements in precision medicine and improve drug development success rates.
- Precision Medicine Acceleration: Merck will leverage the Atlas to enhance precision medicine approaches in its drug discovery pipelines, which is expected to improve the efficiency and effectiveness of new drug development, thereby strengthening its position in the competitive pharmaceutical market.
- Positive Market Reaction: Currently, Illumina's stock is trading at $148.51, up 2.04% on Nasdaq, reflecting market optimism regarding its new product and strategic direction, which may further bolster investor confidence.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
